Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 32, 2011, Pages 13035-13040

  Jones II, Douglas S ^a   Tsai, Ping Chuan ^a   Cochran, Jennifer R ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; PEPTIDE FRAGMENT; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; HUMAN; KRINGLE DOMAIN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; TEMPERATURE; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; DOGS; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; POINT MUTATION; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MET;

EID: 80052010599     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1102561108     Document Type: Article

References (38)

1. Uehara Y., et al. (1995) Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373:702-705.
2. Schmidt C., et al. (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373:699-702.
3. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768-771.
4. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640)
5. Eder J.P., VandeWoude G.F., Boerner S.A., LoRusso P.M. (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214.
6. Jones D.S., Silverman A.P., Cochran J.R. (2008) Developing therapeutic proteins by engineering ligand-receptor interactions. Trends Biotechnol 26:498-505.
7. Donate L.E., et al. (1994) Molecular evolution and domain structure of plasminogenrelated growth factors (HGF/SF and HGF1/MSP). Protein Sci 3:2378-2394.
8. Gherardi E., et al. (2006) Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 103:4046-4051.
9. Kong-Beltran M., Stamos J., Wickramasinghe D. (2004) The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6:75-84. (Pubitemid 38903163)
10. Gherardi E., et al. (2003) Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 100:12039-12044. (Pubitemid 37271511)
11. Basilico C., Arnesano A., Galluzzo M., Comoglio P.M., Michieli P. (2008) A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 283:21267-21277.
12. Mazzone M., et al. (2004) An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 114:1418-1432. (Pubitemid 40385573)
13. Kirchhofer D., et al. (2007) Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Natl Acad Sci USA 104:5306-5311. (Pubitemid 47175676)
14. Date K., Matsumoto K., Shimura H., Tanaka M., Nakamura T. (1997) HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 420:1-6. (Pubitemid 28037188)
15. Schwall R.H., et al. (1996) Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J Cell Biol 133:709-718. (Pubitemid 26163342)
16. Lietha D., Chirgadze D.Y., Mulloy B., Blundell T.L., Gherardi E. (2001) Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J 20:5543-5555. (Pubitemid 33010032)
17. Chirgadze D.Y., et al. (1999) Crystal structure of the NK1 fragment of HGF/SF suggests a novelmode for growth factor dimerization and receptor binding. Nat Struct Biol 6:72-79. (Pubitemid 29232427)
18. Youles M., et al. (2008) Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J Mol Biol 377:616-622.
19. Tolbert W.D., et al. (2007) A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc Natl Acad Sci USA 104:14592-14597. (Pubitemid 350003189)
20. Tolbert W.D., Daugherty-Holtrop J., Gherardi E., VandeWoude G., Xu H.E. (2010) Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci USA 107:13264-13269.
21. Lokker N.A., et al. (1992) Structure-function analysis of hepatocyte growth factor: Identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 11:2503-2510.
22. Ma P.C., et al. (2003) c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-6281. (Pubitemid 37255174)
23. Stahl S.J., et al. (1997) Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J 326:763-772. (Pubitemid 27438050)
24. Venyaminov S., Baikalov I.A., Shen Z.M., Wu C.S., Yang J.T. (1993) Circular dichroic analysis of denatured proteins: Inclusion of denatured proteins in the reference set. Anal Biochem 214:17-24. (Pubitemid 23300347)
25. Holmes O., et al. (2007) Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol 367:395-408. (Pubitemid 46295423)
26. Chao G., et al. (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1:755-768.
27. Boder E.T., Wittrup K.D. (2000) Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 328:430-444.
28. Shusta E.V., Holler P.D., Kieke M.C., Kranz D.M., Wittrup K.D. (2000) Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 18:754-759. (Pubitemid 30460692)
29. Shusta E.V., Kieke M.C., Parke E., Kranz D.M., Wittrup K.D. (1999) Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J Mol Biol 292:949-956. (Pubitemid 29481708)
30. Hackel B.J., Ackerman M.E., Howland S.W., Wittrup K.D. (2010) Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol 401:84-96.
31. Cochran J.R., Kim Y.S., Lippow S.M., Rao B.M., Wittrup K.D. (2006) Improved mutants from directed evolution are biased to orthologous substitutions. Protein Eng Des Sel 19:245-253.
32. Lokker N.A., Presta L.G., Godowski P.J. (1994)Mutational analysis andmolecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng 7:895-903. (Pubitemid 24219959)
33. Takahara T., et al. (2008) Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology 47:2010-2025. (Pubitemid 351945568)
34. Cassano M., et al. (2008) Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. PLoS One 3:e3223.
35. Michieli P., et al. (2002) An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nat Biotechnol 20:488-495. (Pubitemid 34495936)
36. Sinha Roy R., et al. (2010) Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proc Natl Acad Sci USA 107:13608-13613.
37. Zaccolo M., Williams D.M., Brown D.M., Gherardi E. (1996) An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J Mol Biol 255:589-603. (Pubitemid 26107188)
38. Swers J.S., Kellogg B.A., Wittrup K.D. (2004) Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res 32:e36.